The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.

ABSTRACT:

Background

Neuroblastoma (NB), the most common extracranial solid malignancy in children, carries a poor prognosis in high-risk disease, thus requiring novel therapeutic approaches. Survivin is overexpressed in NB, has pro-mitotic and anti-apoptotic functions, and impacts on oxidative phosphorylation (OXPHOS) and aerobic glycolysis. The subcellular localization and hence function of survivin is directed by the GTPase Ran.

Aim

To determine efficacy and modes of action of the survivin-Ran inhibitor LLP-3 as a potential novel therapy of NB.

Methods

Survivin and Ran mRNA expression in NB tumors was correlated to patient survival. Response to LLP-3 in NB cell lines was determined by assays for viability, proliferation, apoptosis, clonogenicity and anchorage-independent gro

SUBMITTER: Galiger C 

PROVIDER: S-EPMC10676583 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature